Jose Carmona
Director of Finance/CFO chez ADC THERAPEUTICS SA
Fortune : 645 438 $ au 31/03/2024
Profil
Jose Carmona is currently the Director at HotSpot Therapeutics, Inc. and the Chief Financial Officer at ADC Therapeutics SA. He previously worked as the Director at Senda Biosciences, Inc., Chief Financial Officer, Treasurer & Senior VP at Radius Health, Inc., CFO-Alcon Europe, Middle East & Africa at Novartis AG, Chief Financial Officer at Innocoll AG, Chief Financial & Accounting Officer at Rubius Therapeutics, Inc., and Chief Financial Officer at Innocoll Holdings Plc.
Mr. Carmona received his undergraduate degree from Universidad Técnica Federico Santa María and his MBA from Columbia Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ADC THERAPEUTICS LTD
0,17% | 01/02/2024 | 143 750 ( 0,17% ) | 645 438 $ | 31/03/2024 |
Postes actifs de Jose Carmona
| Sociétés | Poste | Début |
|---|---|---|
| ADC THERAPEUTICS SA | Director of Finance/CFO | 19/12/2022 |
HotSpot Therapeutics, Inc.
 HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Director/Board Member | - |
Anciens postes connus de Jose Carmona
| Sociétés | Poste | Fin |
|---|---|---|
| RUBIUS THERAPEUTICS | Director of Finance/CFO | 15/11/2022 |
| RADIUS HEALTH, INC. | Director of Finance/CFO | 24/09/2020 |
| INNOCOLL HOLDINGS PLC | Director of Finance/CFO | 01/05/2017 |
Innocoll AG
 Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | Director of Finance/CFO | 01/01/2017 |
| NOVARTIS AG | Corporate Officer/Principal | 01/01/2015 |
Formation de Jose Carmona
| Universidad Técnica Federico Santa María | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| ADC THERAPEUTICS SA | Health Technology |
| Entreprise privées | 6 |
|---|---|
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | Health Technology |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Innocoll Holdings Plc
 Innocoll Holdings Plc Pharmaceuticals: MajorHealth Technology Innocoll Holdings Plc operates as a pharmaceutical company. It focuses on the development and commercialization of pharmaceutical technologies to meet healthcare challenges. The firm's late-stage product pipeline is focused on addressing patient needs for postsurgical pain management. The company was founded in 1997 and is headquartered in Athlone, Ireland. | Health Technology |
HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Health Technology |
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
